Cargando…

Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis

OBJECTIVE: The aim of the study was to analyze the efficacy of double-low dynamic contrast-enhanced CT (DCE-CT) and hepatic extracellular volume fraction (fECV) in the diagnosis of liver fibrosis (LF). METHODS: A total of 200 patients with LF and cirrhosis who underwent the histopathological examina...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhandong, Liu, Yanxia, Nie, Yuanwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402376/
https://www.ncbi.nlm.nih.gov/pubmed/36072627
http://dx.doi.org/10.1155/2022/8089914
_version_ 1784773162550951936
author Liang, Zhandong
Liu, Yanxia
Nie, Yuanwen
author_facet Liang, Zhandong
Liu, Yanxia
Nie, Yuanwen
author_sort Liang, Zhandong
collection PubMed
description OBJECTIVE: The aim of the study was to analyze the efficacy of double-low dynamic contrast-enhanced CT (DCE-CT) and hepatic extracellular volume fraction (fECV) in the diagnosis of liver fibrosis (LF). METHODS: A total of 200 patients with LF and cirrhosis who underwent the histopathological examination of liver biopsy and multiphase DCE-CT of the liver at the same time in our hospital (January 2020–December 2020) were selected as the research subjects, and the degree of liver fibrosis was staged according to pathological criteria to analyze the clinical diagnostic value of double-low DCE-CT and fECV. RESULTS: Compared with the S2–S4 group, the S1 group had obviously higher Eaorta and HCT values (P < 0.05), a lower fECV value (P < 0.001), and lower serum IVC and LN levels (P < 0.001). Serum IVC and LN levels were positively correlated with fECV (r(1) = 0.803 and r(2) = 0.890; P < 0.001). The fECV had the highest specificity and negative predictive value in the diagnosis of S1 and had the highest sensitivity and positive predictive value in the diagnosis of S2–S4. CONCLUSION: The double-low DCE-CT and fECV can provide a reliable basis for the clinical diagnosis of LF, and their results will provide a new direction for the treatment of LF and have a high application value in the clinical practice.
format Online
Article
Text
id pubmed-9402376
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94023762022-09-06 Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis Liang, Zhandong Liu, Yanxia Nie, Yuanwen Contrast Media Mol Imaging Research Article OBJECTIVE: The aim of the study was to analyze the efficacy of double-low dynamic contrast-enhanced CT (DCE-CT) and hepatic extracellular volume fraction (fECV) in the diagnosis of liver fibrosis (LF). METHODS: A total of 200 patients with LF and cirrhosis who underwent the histopathological examination of liver biopsy and multiphase DCE-CT of the liver at the same time in our hospital (January 2020–December 2020) were selected as the research subjects, and the degree of liver fibrosis was staged according to pathological criteria to analyze the clinical diagnostic value of double-low DCE-CT and fECV. RESULTS: Compared with the S2–S4 group, the S1 group had obviously higher Eaorta and HCT values (P < 0.05), a lower fECV value (P < 0.001), and lower serum IVC and LN levels (P < 0.001). Serum IVC and LN levels were positively correlated with fECV (r(1) = 0.803 and r(2) = 0.890; P < 0.001). The fECV had the highest specificity and negative predictive value in the diagnosis of S1 and had the highest sensitivity and positive predictive value in the diagnosis of S2–S4. CONCLUSION: The double-low DCE-CT and fECV can provide a reliable basis for the clinical diagnosis of LF, and their results will provide a new direction for the treatment of LF and have a high application value in the clinical practice. Hindawi 2022-08-17 /pmc/articles/PMC9402376/ /pubmed/36072627 http://dx.doi.org/10.1155/2022/8089914 Text en Copyright © 2022 Zhandong Liang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liang, Zhandong
Liu, Yanxia
Nie, Yuanwen
Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title_full Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title_fullStr Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title_full_unstemmed Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title_short Efficacy Analysis of Double-Low Dynamic Contrast-Enhanced CT and Hepatic Extracellular Volume Fraction in the Diagnosis of Liver Fibrosis
title_sort efficacy analysis of double-low dynamic contrast-enhanced ct and hepatic extracellular volume fraction in the diagnosis of liver fibrosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402376/
https://www.ncbi.nlm.nih.gov/pubmed/36072627
http://dx.doi.org/10.1155/2022/8089914
work_keys_str_mv AT liangzhandong efficacyanalysisofdoublelowdynamiccontrastenhancedctandhepaticextracellularvolumefractioninthediagnosisofliverfibrosis
AT liuyanxia efficacyanalysisofdoublelowdynamiccontrastenhancedctandhepaticextracellularvolumefractioninthediagnosisofliverfibrosis
AT nieyuanwen efficacyanalysisofdoublelowdynamiccontrastenhancedctandhepaticextracellularvolumefractioninthediagnosisofliverfibrosis